4-[(1E)-2-(8,8-二甲基-5,6,7,8-四氢萘-2-基)丙-1-烯-1-基]苯甲酸 | 89315-18-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 4-[(1E)-2-(8,8-二甲基-5,6,7,8-四氢萘-2-基)丙-1-烯-1-基]苯甲酸
• 中文别名: 4-[(1E)-2-(8,8-二甲基-5,6,7,8-四氢-2-萘基)-1-丙烯-1-基]苯甲酸
• 英文名称: (E)-4-(2-(5,6,7,8-Tetrahydro-8,8-dimethyl-2-naphthalenyl)-1-propenyl)benzoic acid
• 英文别名: 4-[(E)-2-(8,8-dimethyl-6,7-dihydro-5H-naphthalen-2-yl)prop-1-enyl]benzoic acid
• CAS: 89315-18-4
• 化学式: C₂₂H₂₄O₂
• 分子量: 320.4
• InChiKey: KZFIKZMCPAIKBF-FYWRMAATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Use of retinoids to treat high blood pressure and other cardiovascular disease
  申请人：——

  公开号：US20030008919A1

  公开（公告）日：2003-01-09

  This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.

  本发明提供了治疗哺乳动物疾病的方法，该疾病的特征是通过抑制细胞钙离子流入而改善症状。这些方法包括向哺乳动物施用有效量的维甲酸和药理学上可接受的赋形剂。
• Composition pharmaceutique ou cosmétique contenant en association un rétinoîde et un stérol
  申请人：CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA

  公开号：EP0465343B1

  公开（公告）日：1994-06-15
• PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE
  申请人：Larsen, Lars, Michael

  公开号：EP1727529A2

  公开（公告）日：2006-12-06
• Prevention of Retinopathy by Inhibition of the Visual Cycle
  申请人：Larsen Michael Lars

  公开号：US20070249713A1

  公开（公告）日：2007-10-25

  The invention relates to compounds capable of inhibiting the visual cycle and/or dark adaptation and their use for treatment and prevention of non-degenerative retinal diseases with specific emphasis on the prevention and treatment of diabetic retinopathy, retinopathy of prematurity, branch retinal vein occlusion, central retinal vein occlusion, open-angle glaucoma, veovascular glaucoma, and other diseases of the retinal and/or optic nerve where an imbalance between metabolic demand and blood supply contribute to the development of tissue damage. The invention furthermore relates to pharmaceutical compositions comprising such compounds.
• CaM Kinase II Inhibitor Improves Retinoic Acid Therapy and Inhibits the Proliferation of Myeloid Leukemia Cells
  申请人：Collins Steven J.

  公开号：US20080255244A1

  公开（公告）日：2008-10-16

  A method of treating a cancer (e.g., myeloid leukemia) in a subject in need thereof, is carried out by administering the subject a CaM kinase II (CaMK II) inhibitor. In some embodiments, the CaMK II inhibitor is administered concurrently with a retinoid. In some embodiments, the CaMK II inhibitor is CaMK II gamma inhibitor. Compositions and formulations useful for carrying out such methods are also described.